Dr RR Baliga's "Got Knowledge Doc" Podkast

🧠 John Locke: Experience • Liberty • Toleration   Born a physician-philosopher, Locke championed empiricism — the idea that knowledge begins with experience, not dogma. His tabula rasa shaped modern psychology, while his Two Treatises of Government defined rights, consent, and freedom that echo through modern democracies.   For clinicians, his legacy reminds us to: 🔹 Trust observation and eviden...

🚀 VESALIUS-CV delivers powerful evidence : in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19% , with LDL-C lowered to a median of 45 mg/dL .   💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events.   🫀 Strong science. Clear si...

🫀 Septic Shock, Refined at the Fingertips ⏱️   A powerful new JAMA (2025) trial brings us one step closer to truly personalized resuscitation. The ANDROMEDA-SHOCK-2 study shows that targeting capillary refill time (CRT) — a simple bedside sign — can shorten time on organ support vs usual care, without increasing mortality.   Key insight: Sometimes the most elegant solutions are low-tech, high-tou...

🚨 SOFA-2 arrives — a thoughtful evolution in critical care scoring 🧠🫁🫀   After nearly 30 years, the SOFA score has been modernized using data from >3.3 million ICU patients across 9 countries. The updated SOFA-2 incorporates contemporary respiratory and cardiovascular supports (HFNC, NIPPV, vasopressors, ECMO) and refines thresholds while preserving simplicity and bedside usability.   A meanin...

SOFA-2 is here — a major advance in assessing organ dysfunction in critical illness 🧠🫁❤️   Three decades after the original SOFA score, this updated framework reflects modern ICU practice — integrating contemporary organ support (ventilation, vasopressors, RRT), delirium recognition, and global feasibility across resource settings 🌍📊   Validated in 3.3M+ ICU patients across 9 countries — a rem...

💔 Peripartum Cardiomyopathy: When a Mother's Heart Fights for Two   Peripartum cardiomyopathy is a leading yet often missed cause of maternal morbidity and mortality—striking late in pregnancy or months postpartum. Early suspicion, timely echo, and guideline-directed therapy save lives. 🩺   🧠 Bromocriptine, careful anticoagulation, and multidisciplinary care are reshaping outcomes, but global d...

Rethinking "default lines" in the ICU 🧠🚑   A landmark NEJM trial shows that in patients with shock, deferring arterial catheterization and using automated cuff monitoring was noninferior for 28-day mortality — and reduced catheter-related complications.   A gentle reminder: not every sick patient needs a needle to be well cared for.   Precision isn't only invasive — sometimes it's thoughtful, me...

🌙 Bright Nights, Higher Heart Risk ❤️‍🩹   New findings in JAMA Network Open highlight that greater exposure to artificial light at night is associated with significantly increased risks of coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, and stroke — independent of sleep duration, lifestyle factors, and genetics.   💡 Clinical takeaway: Protecting circadian rhy...

The immune clock starts earlier than we think ⏳🧬   A landmark Nature study shows that immune aging begins quietly in midlife — decades before clinical frailty.   Using >16M single-cell profiles and longitudinal vaccine responses, researchers found: • Stable, early transcriptional drift in naïve & memory T cells • A subtle TH2 shift that may weaken antiviral antibody quality • Reduced IgG class-s...

🫀 TAVR or SAVR? The 7-Year Truth   New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes.   🔎 Highlights • Composite events: 34.6% (TAVR) vs 37.2% (SAVR) • Mortality: 19.5% vs 16.8% • Va...

🌿 Spinoza: Reason, Nature, Freedom   Today's deck explores Baruch Spinoza — the quietly revolutionary Dutch philosopher who shaped rationalism, modern biblical criticism, and secular democracy.   He saw God = Nature , championed intellectual freedom , and argued that understanding our emotions transforms them — not far from cognitive-behavioral ideas we use in modern medicine.   His reminder feel...

A new era for complex mitral regurgitation. The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER.   A third pathway for mitral disease is emerging—one built on...

🧬 Can we rejuvenate the aging immune system?   A remarkable Nature Biotechnology study shows that a rare population of periostin-positive mesenchymal niche cells can rebuild the adult thymus , recruit new T-cell progenitors, and restore immune responses after injury.   By harnessing CCL19-expressing stromal support, the authors demonstrate a path toward immune renewal in aging, cancer therapy rec...

🩺🎗️ Cardio-Oncology Insight: Not Every Breast Cancer Survivor Needs a Cardiologist   As breast cancer survivorship grows, understanding who truly benefits from long-term cardiac follow-up becomes essential. An important editorial in JAMA Oncology underscores a key principle: risk-stratified care, not reflex surveillance .   👩‍⚕️🔍 Age and traditional cardiovascular risk factors outweigh treatmen...

🧬 Can we rejuvenate the aging immune system? A new Nature Aging trial suggests we might be closer than we thought.   In 50 healthy adults aged 45–70, urolithin A —a mitophagy activator—improved immune fitness over just 28 days: ✅ ↑ naïve CD8⁺ T cells ✅ ↓ exhaustion markers (TOX) ✅ ↑ mitochondrial biogenesis (PGC-1α) ✅ ↑ fatty-acid oxidation capacity ✅ ↑ NK cell and monocyte function ✅ ↑ bac...

🫀 Personalizing DAPT: When "One Size Fits All" Fails 🕊️💊   The HOST-BR trial in The Lancet offers an important clinical lesson: Bleeding risk should guide antiplatelet duration after PCI — not habit, not inertia.   🔍 Key insight   In ARC-HBR patients, 1-month DAPT was not non-inferior to 3 months In non-HBR patients, 3-month DAPT was non-inferior to 12 months and reduced bleeding     🧠 Clinica...

🚨 New Pharmacotherapy for Obstructive Sleep Apnoea 🌙💊 In a landmark Phase 2 trial published in The Lancet , sultiame— a carbonic anhydrase inhibitor—showed dose-dependent reduction in AHI and improved nocturnal oxygenation in adults with moderate–severe OSA.   💡 Key insights: • 298 participants across 5 European countries • 200 mg daily delivered the best efficacy-to-tolerability balance • Ben...

  📢 New Study Alert 🩺💊 In JAMA Internal Medicine, a national analysis reveals that using the PREVENT risk calculator (vs Pooled Cohort Equations) dramatically reduces the number of U.S. adults aged 40–59 eligible for aspirin in primary prevention of cardiovascular disease. Among 7.6 million current aspirin users, >96% wouldn't qualify by PREVENT 🤯. Time to rethink our calculators and consider...

🧠 TACSI Trial in NEJM (Sep 2025) challenges the status quo on dual antiplatelet therapy after CABG for ACS! 👨‍⚕️ 2201 patients across 5 Nordic countries 💊 Ticagrelor + Aspirin ≠ better outcomes vs Aspirin alone 📉 No reduction in death, MI, stroke, or revascularization 🩸 But bleeding (4.9% vs 2.0%) & dyspnea (18.2% vs 6.4%) increased 📚 Guidelines may need rethinking.   📖 Jeppsson A et al. N...

🧪 NEO-MINDSET Trial 🇧🇷 published in NEJM asks: Can we safely drop aspirin early after PCI in acute coronary syndromes (ACS)?   💊 Monotherapy with ticagrelor/prasugrel reduced bleeding 🩸 but increased early ischemic events 💥 vs dual antiplatelet therapy (DAPT). ❗ Noninferiority for major adverse cardiovascular events was not met .   🔍 DAPT still stands tall in early post-PCI ACS care. Kudos t...

🚨 New in NEJM — The ALASCCA Trial 🧬 Low-dose aspirin (160 mg/day) reduced colorectal cancer recurrence in patients with PIK3CA , PIK3R1 , or PTEN mutations 🎯   ✅ 3-year recurrence: 7.7% (aspirin) vs 14–17% (placebo) ✅ Group A HR : 0.49 | Group B HR : 0.42 ✅ NNT as low as 6 in stage III rectal cancer 💥 ⚠️ Slight increase in adverse events   🧠 Editorial calls it a new standard of care : 🔬 G...

💡 TARGET-FIRST trial (NEJM, Aug 2025) shows that in low-risk AMI patients post-PCI with complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy is noninferior to dual antiplatelet therapy— with 54% fewer bleeding events 🩸🛑💊   ⚖️ A modern, patient-tailored antiplatelet strategy—backed by potent P2Y12 inhibitors and smart selection—might just be the new norm i...

💡 "Cogito, ergo sum" — I think, therefore I am. René Descartes laid the foundation of modern Western philosophy and scientific reasoning, linking algebra to geometry, and mind to body.  🧠📐 His legacy reminds healthcare professionals to unite  reason with compassion — science with soul. ❤️⚕️

💊🫀 Aspirin in the Crosshairs? The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation. 📉 Adding aspirin led to: • ↑ Ischemic events (HR 1.53; P=0.02 ) • ↑ Mortality (HR 1.72; P=0.01 ) • ↑ Major bleeding (HR 3.35; P

🧠💥 Could lead poisoning have helped shape human evolution? A bold new hypothesis suggests that Homo sapiens may have survived while Neanderthals and Denisovans vanished—thanks to genetic defenses against environmental lead. 🧬   By analyzing fossil teeth 🦷 and testing brain organoids 🧪, researchers found that ancient lead exposure disrupted key language-related genes (like FOXP2 )—but not in m...